Attitudes, beliefs toward end-of-life care differ between hematologic, solid tumor specialists
the ONA take:
Researchers at the University of Texas MD Anderson Cancer Center conducted a survey to compare the attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
They randomly surveyed 120 hematologists and 120 solid tumor oncologists at the institution; 182 clinicians (76%) responded.
The survey questions examined the participants’ attitudes toward various aspects of end-of-life care, including use of palliative systemic therapy.
The researchers found significant differences in attitudes and beliefs toward end-of-life care. Hematologic specialty and comfort level with prescribing treatment to patients with Eastern Cooperative Oncology Group performance status 4 and an expected survival of 1 month were associated with the decision to treat in the last month of life.
Survey compares attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|